Quoin Pharma director granted 21,709 share options

Quoin Pharmaceuticals director granted stock options Quoin Pharmaceuticals, Ltd. reported that director Anthony James Culverwell received a grant of share options on February 4, 2026.

Rhea-AI Filing Summary

Quoin Pharmaceuticals director granted stock options

Quoin Pharmaceuticals, Ltd. reported that director Anthony James Culverwell received a grant of share options on February 4, 2026. The award covers 21,709 American Depositary Shares (ADSs), each with an exercise price of $7.37 per ADS and no purchase price for the grant itself.

Each ADS represents thirty-five ordinary shares of the company. The option vests over four years, with 20% vesting on each of February 4, 2027, February 4, 2028 and February 4, 2029, and the remaining 40% vesting on February 4, 2030. After this transaction, Culverwell directly holds options over 21,709 ADSs.

Insider Trade Summary

Grant/Award: 21,709 shares

Grant/Award 1 txn

Insider Culverwell Anthony James

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	21,709	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 21,709 contracts (Direct)

Footnotes (2)

1. F1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
2. F2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Quoin Pharmaceuticals (QNRX) Form 4 filing report?

The Form 4 reports a stock option grant to director Anthony James Culverwell. He received options over 21,709 American Depositary Shares, giving him the right to buy Quoin Pharmaceuticals ADSs at a fixed exercise price over a multi‑year vesting schedule.

How many Quoin Pharmaceuticals (QNRX) ADS options were granted?

The filing shows a grant of options over 21,709 American Depositary Shares. These options give the director the right to acquire up to 21,709 ADSs, subject to vesting conditions, which are spread over four years starting in February 2027.

What is the exercise price of the new Quoin (QNRX) stock options?

The options have an exercise price of $7.37 per American Depositary Share. This means the director can buy each ADS at $7.37 once the options vest, regardless of the market price at that future time, according to the grant terms.

How do the Quoin Pharmaceuticals (QNRX) options vest over time?

The options vest in four annual installments. According to the filing, 20% vests on each of February 4, 2027, 2028, and 2029, with the remaining 40% vesting on February 4, 2030, if the vesting conditions are met.

What does each Quoin Pharmaceuticals (QNRX) ADS represent?

Each American Depositary Share represents thirty-five ordinary shares of Quoin Pharmaceuticals. The filing states that the option grant and its exercise price are quoted in ADS terms, so 21,709 ADSs correspond to a multiple of the company’s ordinary shares.

Is the Quoin (QNRX) Form 4 transaction a purchase in the open market?

No. The transaction reflects an option grant coded “A” for acquisition, with a price of $0 for the derivative security. It is an award of options, not an open‑market share purchase or sale, and follows the vesting schedule described.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Culverwell Anthony James

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VA 20148

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$7.37(1)	02/04/2026		A		21,709(1)		(2)	02/04/2036	ADS	21,709(1)	$0	21,709(1)	D

Explanation of Responses:

1. The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

2. The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

	/s/ Anthony James Culverwell	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.